Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 15/20 | 0.77 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.72 |
| ▸ | CPT2 | P23786 | 1/20 | 0.45 |
| ▸ | CPT1A | P50416 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3753387 | 1.00 | S1PR1 (0.77) | S1PR1S1PR5CPT2CPT1ACHRNB2 | |
| SCHEMBL3428474 | 1.00 | S1PR1 (0.77) | S1PR1S1PR5CPT2CPT1ACHRNB2 | |
| SCHEMBL950796 | 0.87 | S1PR1 (1.00) | S1PR1S1PR5S1PR4 | |
| SCHEMBL3433607 | 0.87 | S1PR1 (1.00) | S1PR1S1PR5S1PR4 | |
| SCHEMBL3747647 | 0.87 | S1PR1 (1.00) | S1PR1S1PR5S1PR4 | |
| SCHEMBL3755388 | 0.86 | S1PR1 (0.80) | S1PR1S1PR5 | |
| SCHEMBL3426855 | 0.86 | S1PR1 (0.80) | S1PR1S1PR5 | |
| SCHEMBL3750051 | 0.86 | S1PR1 (0.80) | S1PR1S1PR5 | |
| SCHEMBL3746061 | 0.85 | S1PR1 (0.79) | S1PR1S1PR5S1PR4 | |
| SCHEMBL3753888 | 0.85 | S1PR1 (0.79) | S1PR1S1PR5S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101981030-A | Dihydro- 1H- pyrrolo [1,2-a] indol-1-yl carboxylic derivatives which act as S1P1 agonists | ARENA PHARM INC | 2011-02-23 | — | — | CN | disclosed |
| US-20100292233-A1 | DIHYDRO-1H-PYRROLO[1,2-A]INDOL-1-YL CARBOXYLIC ACID DERIVATIVES WHICH ACT AS S1P1 AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292233-A1 | DIHYDRO-1H-PYRROLO[1,2-A]INDOL-1-YL CARBOXYLIC ACID DERIVATIVES WHICH ACT AS S1P1 AGONISTS | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR5 4/4885CPT2 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.